FDA investigates CT scan radiation overexposure risk
This article was originally published in The Gray Sheet
FDA is conducting a safety investigation of CT brain perfusion scans performed at a single facility after learning of radiation overexposures at that location. Over an 18-month period, 206 patients at the facility received radiation doses at approximately eight times the appropriate level, in some cases resulting in hair loss and erythema, FDA says. While the event involved just one facility, "this situation may reflect more widespread problems with CT quality assurance programs and may not be isolated to this particular facility or this imaging procedure," the agency writes in an Oct. 8 initial safety notification. Hospitals and CT facilities should review CT protocols and carefully monitor radiation dose indices before and after scans, FDA says
You may also be interested in...
FDA is investigating hundreds of cases of radiation overexposure from computed tomography (CT) imaging scans to determine whether the overdoses were caused by human error or a problem with the devices
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.